30762-00-6

Usage

Uses

Used in Pharmaceutical Industry:
4-ISOBUTOXY-BENZOIC ACID is used as an analgesic for the relief of mild to moderate pain, such as headaches, muscle aches, and menstrual cramps. Its ability to alleviate pain is attributed to its capacity to reduce prostaglandin synthesis, thereby decreasing the sensation of pain.
4-ISOBUTOXY-BENZOIC ACID is used as an anti-inflammatory agent for conditions characterized by inflammation, such as arthritis. It helps to reduce swelling and tenderness in the affected joints, improving the patient's mobility and comfort.
4-ISOBUTOXY-BENZOIC ACID is used as an antipyretic to reduce fever by lowering the body's temperature set point. This is particularly useful in cases of minor infections or other conditions that cause an elevated body temperature.
4-ISOBUTOXY-BENZOIC ACID is also used in various formulations, such as tablets, capsules, and topical gels, to cater to different patient preferences and needs. Its availability over-the-counter in many countries underscores its widespread use and accessibility for self-medication of common ailments.
While generally well tolerated, 4-ISOBUTOXY-BENZOIC ACID may cause gastrointestinal side effects in some individuals, highlighting the importance of following recommended dosages and consulting healthcare professionals for proper use.

InChI:InChI=1/C11H14O3/c1-8(2)7-14-10-5-3-9(4-6-10)11(12)13/h3-6,8H,7H2,1-2H3,(H,12,13)/p-1

Upstream product

• 1015423-08-1 ethyl 4-(2-methylpropoxy)benzoate 
• 78-77-3 Isobutyl bromide 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 513-38-2 Isobutyl iodide 
• 99-96-7 4-hydroxy-benzoic acid 
• 78-83-1 2-methyl-propan-1-ol 
• 94-36-0 dibenzoyl peroxide 
• 99-78-5 isobutyl p-nitrobenzoate 
• 13259-29-5 sodium isobutoxide 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 124-38-9 carbon dioxide 
• 30752-23-9 4-bromophenyl iso-butyl ether 
• 124403-90-3 methyl 4-(2-methylpropoxy)benzoate 

Downstream Products

• 67032-10-4 4-isobutoxy-benzoic acid-[3-(2-methyl-piperidino)-propylester]; hydrochloride 
• 40782-45-4 4-(2-methylpropoxy)benzoyl chloride 
• 748183-81-5 4-isobutoxy-N-[4-(3-oxopyrrolidin-1-yl)-phenyl]-benzamide 
• 4734-09-2 1-[4-(2-methylpropyloxy)phenyl]methanamine 
• 1030513-44-0 4-isobutoxybenzamide 
• 706779-91-1 N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′-(4-(2-methylpropyloxyl)phenylmethyl)carbamide 
• 1373823-20-1 4-(2-methylpropoxy)-N-[8-methyl-3-(pyrrolidin-1-ylmethyl)-quinolin-7-yl]benzamide 

Relevant academic research and scientific papers

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent and low molecular size, while the docking study of compound 6 suggested a large unoccupied hydrophobic pocket, which might be provided more possibility of structure-activity relationship (SAR) study. In this study, we have performed comprehensive SAR and molecular modeling studies based on lead compound 6. All of these efforts resulted in the identification of a novel series of FXR partial agonists. In this series, compound 41 revealed the best activity and strong interaction with binding pocket of FXR. Moreover, compound 41 protected mice against acetaminophen-induced hepatotoxicity by the regulation of FXR-related gene expression and improving antioxidant capacity. In summary, these results suggest that compound 41 is a promising FXR partial agonist suitable for further investigation.

COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES

The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.

Synthetic method of Pimavanserin

The invention belongs to the field of medicine synthesis, and especially relates to a synthetic method of Pimavanserin. According to the synthetic method, 4-hydroxy benzoic acid is taken as a raw material, esterification reaction, alkylation reaction, hydrolysis, acylation reaction, dehydration reduction, and acylation reaction are carried out to obtain an intermediate (9); fluorobenzylamine and N-methyl-4-piperidone are taken as raw materials for reductive amination to obtain intermediate (10); and at last the intermediate (9) and the intermediate (10) are subjected to aminolysis to obtain finished product Pimavanserin. The initial raw materials are cheap and easily available; reaction conditions are mild; no column chromatography is needed; and the yield is relatively high.

COMPOUNDS FOR MODULATING AQUAPORINS

The invention relates to compounds of formula (I) pharmaceutical compositions thereof and methods for modulating aquaporin 9.

Thermodynamic properties of isomeric iso-butoxybenzoic acids: Experimental and theoretical study

Standard (p° = 0.1 MPa) molar enthalpies of formation at the temperature T = 298.15 K of the 2-, 3-, and 4-iso-butoxybenzoic acids were measured using the combustion calorimetry. Standard molar enthalpies of vaporization and sublimation were derived from

Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3- aminomethylquinolines: Reducing human ether-a-go-go-related gene (hERG) associated liabilities

Recently, we discovered 3-aminomethylquinoline derivative 1, a selective, highly potent, centrally acting, and orally bioavailable human MCH receptor 1 (hMCHR1) antagonist, that inhibited food intake in F344 rats with diet-induced obesity (DIO). Subsequent investigation of 1 was discontinued because 1 showed potent hERG K+ channel inhibition in a patch-clamp study. To decrease hERG K+ channel inhibition, experiments with ligand-based drug designs based on 1 and a docking study were conducted. Replacement of the terminal p-fluorophenyl group with a cyclopropylmethoxy group, methyl group introduction on the benzylic carbon at the 3-position of the quinoline core, and employment of a [2-(acetylamino)ethyl]amino group as the amine portion eliminated hERG K+ channel inhibitory activity in a patch-clamp study, leading to the discovery of N-{3-[(1R)-1-{[2-(acetylamino)ethyl]amino} ethyl]-8-methylquinolin-7-yl}-4-(cyclopropylmethoxy)benzamide (R)-10h. The compound (R)-10h showed potent inhibitory activity against hMCHR1 and dose-dependently suppressed food intake in a 2-day study on DIO-F344 rats. Furthermore, practical chiral synthesis of (R)-10h was performed to determine the molecule's absolute configuration.

ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS

The present invention relates to pharmaceutical compounds for delivering active agents, such as biologically or chemically active agents, to a target. The invention also relates to pharmaceutical compositions comprising at least one delivery agent compound of the present invention and at least one active agent, and unit dosage forms comprising such compositions. Methods for the preparation and administration of the pharmaceutical compositions are also disclosed.

COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS

Compositions and methods comprising proteinase activated receptor antagonists are provided. More particularly, the present invention relates to the use of proteins, peptides and molecules that bind to proteinase activated receptor 2, and inhibit the processes associated with the activation of that receptor. More specifically, the present invention provides novel compositions and methods for the treatment of disorders and diseases such as those associated with abnormal cellular proliferation, angiogenesis, inflammation and cancer.

Competing SNAr displacements of nitrite and SN2 displacements on the alkyl groups of alkyl p-nitrobenzoates and o-nitrobenzoates

Several p-nitrobenzoate and o-nitrobenzoate esters have been found to undergo competing SNAr and SN2 reactions with azide, alkoxide, and thiophenoxide ions. SNAr displacement of the nitro group even competes with SN2 displacement on the methyl group of methyl esters 1c and 11. Esters 1a and 1b undergo predominately SNAr displacements with azide, whereas 1c undergoes predominately an SN2 displacement with azide. Both 1b and 1c undergo predominately SNAr reactions with alkoxides and thiophenoxide. The SNAr products from the azide reactions consist of mixtures of p-azidobenzoates, p-aminobenzoates, and 4,4′-azodibenzoates whose compositions depend upon the reaction conditions.